Skip to main content
SpringerLink
Log in
Book cover

NeuroPsychopharmacotherapy pp 1–10Cite as

Side Effects, Contraindications, and Drug-Drug Interactions in the Use of Antiparkinsonian Drugs

  • Living reference work entry
  • First Online:

  • 449 Accesses

Abstract

Since anticholinergics were firstly used as an antiparkinsonian drug over half a century ago, a lot of antiparkinsonian drugs have been developed and are now on the market. Although levodopa is most effective and still the gold standard therapy for Parkinson’s disease (PD), its side effects of motor complication such as wearing off and dyskinesia limited its use and prompted the development of novel antiparkinsonian drugs. Dopamine agonists are most commonly used drugs among them, but their serious side effects such as sleep attack and impulsive-compulsive disorders are also well-recognized. In this chapter we focus on the common and specific side effects of antiparkinsonian drugs as well as their clinically important drug-drug interactions.

This is a preview of subscription content, log in via an institution.

References

  • Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol. 2007;6(9):826–9.

    Article  CAS  Google Scholar 

  • Brooks DJ. Safety and tolerability of COMT inhibitors. Neurology. 2004;62(1 suppl 1):S39–46.

    Article  CAS  Google Scholar 

  • Ceravolo R, et al. Neuropathy and levodopa in Parkinson’s disease: evidence from a multicenter study. Mov Disord. 2013;28(10):1391–7.

    Article  CAS  Google Scholar 

  • Cruz MP. Xadago (Safinamide). A monoamine oxidase B inhibitor for the adjunct treatment of motor symptoms in Parkinson’s disease. PT. 2017;42(10):622–624,637.

    Google Scholar 

  • Doherty KW, et al. Postural deformities in Parkinson’s disease. Lancet Neurol. 2011;10(6):538–49.

    Article  Google Scholar 

  • Frucht S, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52(9):1908–11.

    Article  CAS  Google Scholar 

  • Gibbs MB, et al. Livedo reticularis: an update. J Am Acad Dermatol. 2005;52(6):1009–19.

    Article  Google Scholar 

  • Giovannoni G, et al. Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000;68(4):423–8.

    Article  CAS  Google Scholar 

  • Goralski KB, et al. In vivo analysis of amantadine renal clearance in the uninephrectomized rat: functional significance of in vitro bicarbonate-dependent amantadine renal tubule transport. J Pharmacol Exp Ther. 1999;290(2):496–504.

    CAS  Google Scholar 

  • Horn S, Stern MB. The comparative effects of medical therapies for Parkinson’s disease. Neurology. 2004;63(7 suppl 2):S7–12.

    Article  Google Scholar 

  • Hu XW, et al. Elevated homocysteine levels in levodopa-treated idiopathic Parkinson’s disease: a meta-analysis. Acta Neurol Scand. 2013;128(2):73–82.

    Article  CAS  Google Scholar 

  • Hubsher G, et al. Amantadine. The journey from fighting flu to treating Parkinson disease. Neurology. 2012;78(14):1096–9.

    Article  CAS  Google Scholar 

  • Ives NJ, et al. Monoamine oxidase type B inhibitors in early Parkinson’s disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ. 2004;329(7466):593.

    Article  CAS  Google Scholar 

  • Katzenschlager R, et al. Anticholinergics for symptomatic management of Parkinson’s disease (Cochrane Review). Cochrane Database Syst Rev. 2003;(2):CD003735.

    Google Scholar 

  • Knebel W, et al. Population pharmacokinetic analysis of Istradefylline in healthy subjects and in patients with Parkinson’s disease. J Clin Pharmacol. 2011;51(1):40–52.

    Article  CAS  Google Scholar 

  • Kondo T, et al. A long-term study of Istradefylline safety and efficacy in patients with Parkinson disease. Clin Neuropharmacol. 2015;38(2):41–6.

    Article  CAS  Google Scholar 

  • Molina JA, et al. Pathologic gambling in Parkinson’s disease: a behavioral manifestation of pharmacologic treatment? Mov Disord. 2000;15(5):869–72.

    Article  CAS  Google Scholar 

  • Mori A, Shindou T. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors. Neurology. 2003;61(11 suppl 6):S44–8.

    Article  CAS  Google Scholar 

  • Murata M. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson’s disease. Curr Pharm Des. 2004;10(6):687–93.

    Article  CAS  Google Scholar 

  • Olanow CW. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel Arch Neurol. 2000;57:263–7.

    Article  CAS  Google Scholar 

  • Pfeiffer RF, et al. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease. Parkinsonism Relat Disord. 2007;13(2):93–100.

    Article  Google Scholar 

  • Pringsheim T, et al. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583–90.

    Article  Google Scholar 

  • Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67(1):58–63.

    Article  Google Scholar 

  • Stowe R, et al. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst Rev. 2008;16(2):CD006564.

    Google Scholar 

  • Uncini A, et al. Polyneuropathy associated with duodenal infusion of levodopa in Parkinson’s disease: features, pathogenesis and management. J Neurol Neurosurg Psychiatry. 2015;86(5):490–5.

    Article  Google Scholar 

  • Warren N, et al. Dopamine dysregulation syndrome in Parkinson’s disease: a systematic review of published cases. J Neurol Neurosurg Psychiatry. 2017;88(12):1060-1064.

    Article  Google Scholar 

  • Weintraub D, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3,090 patients. Arch Neurol. 2010;67(5):589–95.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan

    Etsuro Nakanishi & Ryosuke Takahashi

Authors
  1. Etsuro Nakanishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryosuke Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ryosuke Takahashi .

Editor information

Editors and Affiliations

  1. Dept Psychiatry , Psychosomatics & Psychotherapy, University of Würzburg, Medical School Clinical Neurochemistry, Würzburg, Germany

    Peter Riederer

  2. Inst für Psychologische Medizin, Haag, Bayern, Germany

    Gerd Laux

  3. Department of Psychiatry, University of Toronto Department of Psychiatry, Toronto, ON, Canada

    Benoit Mulsant

  4. Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China

    Weidong Le

  5. Fujita Health University School Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

Section Editor information

  1. Fujita Health University School of Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

  2. Institute of Environmental Medicine, Nagoya University, Nagoya, Aichi, Japan

    Toshiharu Nagatsu

  3. Department of Physiological Chemistry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

    Akira Nakashima

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Nakanishi, E., Takahashi, R. (2020). Side Effects, Contraindications, and Drug-Drug Interactions in the Use of Antiparkinsonian Drugs. In: Riederer, P., Laux, G., Mulsant, B., Le, W., Nagatsu, T. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_218-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56015-1_218-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56015-1

  • Online ISBN: 978-3-319-56015-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation